PTK787/ZK222584 [vatalinib] and RAD001 [everolimus] for patients with advanced solid tumors.
Phase of Trial: Phase I
Latest Information Update: 08 Mar 2016
At a glance
- Drugs Everolimus (Primary) ; Vatalanib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 31 Aug 2018 Biomarkers information updated
- 01 Aug 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 08 May 2008 The expected completion date for this trial is now 1 Aug 2009.